Metastatic Squamous Neck Cancer With Occult Primary Completed Phase 1 Trials for Cetuximab (DB00002)

IndicationStatusPhase
DBCOND0030666 (Metastatic Squamous Neck Cancer With Occult Primary)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00397384Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerTreatment